ADMA Biologics Inc (NASDAQ:ADMA) Expected to Earn FY2019 Earnings of ($0.92) Per Share

ADMA Biologics Inc (NASDAQ:ADMA) – Stock analysts at Oppenheimer lowered their FY2019 earnings per share estimates for shares of ADMA Biologics in a report issued on Thursday, November 7th. Oppenheimer analyst L. Gershell now expects that the biotechnology company will earn ($0.92) per share for the year, down from their previous forecast of ($0.90). Oppenheimer also issued estimates for ADMA Biologics’ Q4 2019 earnings at ($0.18) EPS, FY2020 earnings at ($0.37) EPS, FY2022 earnings at $0.47 EPS and FY2023 earnings at $0.66 EPS.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. The company had revenue of $7.22 million for the quarter, compared to analysts’ expectations of $5.71 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.

Several other research firms have also recently issued reports on ADMA. Dawson James cut ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Monday, August 12th. Maxim Group set a $12.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Monday, October 21st. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Finally, ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $10.20.

NASDAQ ADMA opened at $4.31 on Monday. The stock has a market capitalization of $304.89 million, a P/E ratio of -2.97 and a beta of 2.70. ADMA Biologics has a 1 year low of $2.08 and a 1 year high of $6.31. The business’s fifty day moving average is $4.59 and its two-hundred day moving average is $4.26. The company has a debt-to-equity ratio of 1.79, a quick ratio of 7.93 and a current ratio of 10.26.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its holdings in shares of ADMA Biologics by 76.7% during the 2nd quarter. Perceptive Advisors LLC now owns 11,521,102 shares of the biotechnology company’s stock valued at $44,586,000 after acquiring an additional 5,000,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of ADMA Biologics by 47.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock valued at $9,474,000 after acquiring an additional 786,567 shares in the last quarter. BlackRock Inc. grew its holdings in shares of ADMA Biologics by 94.0% during the 2nd quarter. BlackRock Inc. now owns 1,897,484 shares of the biotechnology company’s stock valued at $7,343,000 after acquiring an additional 919,260 shares in the last quarter. Jefferies Group LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter valued at $2,961,000. Finally, Northern Trust Corp grew its holdings in shares of ADMA Biologics by 14.4% during the 2nd quarter. Northern Trust Corp now owns 299,248 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 37,677 shares in the last quarter. Hedge funds and other institutional investors own 59.10% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: Initial Public Offering (IPO)

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit